Antifungal News and Research

RSS

Ground-breaking research helps better understand the threat posed by antifungal drug resistance

Ground-breaking work by university experts in Tennessee, Texas and Swansea is helping develop a better understanding of the growing threat posed by antifungal drug resistance.

4 Apr 2019

Study develops simple, new treatment to fight Candida Albicans fungus

A study led by the UPV/EHU has developed an innovative, simple treatment based uterine stem cells to combat the Candida Albicans fungus, responsible for vaginal candidiasis disease.

5 Feb 2019

SCYNEXIS announces positive results from first interim efficacy analysis of FURI study

SCYNEXIS, Inc., a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from the first interim efficacy analysis of the ongoing FURI study.

1 Feb 2019

Peptide isolated from soil fungi has antitumor and antibacterial properties

A team of scientists from I.M. Sechenov First Moscow State Medical University together with their colleagues isolated a peptide named emericellipsin A from soil fungi.

22 Jan 2019

Research finds how Candida albicans adapt to low oxygen levels to cause infection

Scientists from Umeå university have shown how the yeast Candida albicans can modulate and adapt to low oxygen levels in different body niches to cause infection and to harm the host.

16 Jan 2019

Cloned antibodies show potential to treat, diagnose life-threatening fungal infections

Despite public health efforts, many people who get fungal infections in their blood streams die, even if they can be identified and treated with antifungal drugs. These therapies are often ineffective on their own and increasingly the infections are becoming resistant to treatment with some of the front line antifungal drugs.

11 Dec 2018

Researchers develop biotechnological tool to produce antifungal proteins in plants

Researchers from the Spanish Research Council at the Centre for Research in Agricultural Genomics and the Institute for Plant Molecular and Cellular Biology, in collaboration with the IATA, have developed a biotechnological tool to produce, in a very efficient manner, antifungal proteins in plants.

10 Dec 2018

FDA approves antibacterial drug to treat travelers' diarrhea

The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

17 Nov 2018

Scientists examine FCMs containing silver nanoparticles

Because of their antimicrobial and antifungal properties, silver nanoparticles measuring between one and 100 nanometers in size, are being incorporated outside the United States into a variety of kitchen products known as food contact materials.

9 Nov 2018

That’s a lot of scratch: The $48,329 allergy test

Janet Winston had a rash that wouldn't go away. The English professor from Eureka, Calif., always had been sensitive to ingredients in skin creams and cosmetics. This time, however, the antifungal cream she was prescribed to treat her persistent rash seemed to make things worse. Was she allergic to that, too?

29 Oct 2018

New approach may lead to protective vaccines for immunocompromised patients

A study led by Som Nanjappa at the University of Illinois College of Veterinary Medicine identifies a cellular target that may improve efficacy in vaccines designed to protect immunocompromised individuals from potentially deadly opportunistic infections.

26 Oct 2018

Scientists engineer antiviral peptide that exploits Achilles' heel of Zika virus

Scientists at Nanyang Technological University, Singapore have engineered an antiviral peptide that exploits the Zika virus at its Achilles' heel - the viral membrane - hence stopping the virus from causing severe infections.

24 Oct 2018

Common herbicide compound could help fight hospital-acquired fungal infections

A chemical compound found in common herbicides could help fight hospital-acquired human fungal pathogenic infections, which claim an estimated two million lives per year.

4 Oct 2018

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

The U.S. Food and Drug Administration today approved a new drug, Arikayce, for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex in a limited population of patients with the disease who do not respond to conventional treatment.

29 Sep 2018

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

27 Sep 2018

UTILITY receives FDA approval for Investigational New Drug applications

UTILITY therapeutics Ltd, a pharmaceutical company focused on developing and commercializing antibiotics in the US, today announces that the US Food and Drug Administration has approved the Investigational New Drug applications for mecillinam and pivmecillinam.

19 Sep 2018

Discovery of unusual biosynthetic pathways could aid in the search for new natural products

Bacteria are master engineers of small, biologically useful molecules. A new study in Nature Communications has revealed one of the tricks of this microbial trade: synthesizing and then later inserting a nitrogen-nitrogen bond, like a prefabricated part, into a larger molecule.

12 Sep 2018

Mycovia initiates two Phase 3 clinical trials to evaluate VT-1161 in patients with RVVC

Mycovia Pharmaceuticals, making its official debut as a company developing therapies in women's health and dermatology, today announced the initiation of two Phase 3 clinical trials called VIOLET to evaluate the safety and efficacy of its lead candidate, VT-1161, in patients with recurrent vulvovaginal candidiasis

6 Sep 2018

FDA expands approval of Vertex' cystic fibrosis medicine to treat children aged 12 to <24 months

Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.

16 Aug 2018

Karius Test accurately detects invasive fungal infections, shows study

Karius, a life sciences company transforming infectious disease diagnostics with genomics and data through the innovative use of next-generation sequencing to analyze microbial cell-free DNA, announced today the positive results of a clinical study using blood samples from patients with confirmed invasive fungal infections.

20 Jul 2018